Publications

Bioinformatics (Oxford, England)

Comparative Network Reconstruction using mixed integer programming.

01-09-2018

Key

Cancer cell

Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy.

29-10-2024

Nature reviews. Cancer

Cancer drug-tolerant persister cells: from biological questions to clinical opportunities.

01-10-2024

Molecular oncology

A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm.

01-10-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

01-08-2024

Cancer discovery

Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy.

01-07-2024

Cancer cell

The case for therapeutic overactivation of oncogenic signaling as a potential cancer treatment strategy.

10-06-2024

Gastroenterology

Dual Inhibition of CDK4/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs.

01-06-2024

EMBO reports

The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing.

01-05-2024

Cell

Embracing cancer complexity: Hallmarks of systemic disease.

28-03-2024

Cell reports. Medicine

Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse.

19-03-2024

Proceedings of the National Academy of Sciences of the United States of America

Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.

27-02-2024

Cancer cell

Precision treatment in advanced hepatocellular carcinoma.

12-02-2024

Cell research

LICOB: a powerful organoid platform for drug discovery.

01-01-2024

BJR open

How to 19F MRI: applications, technique, and getting started.

13-11-2023

Molecular oncology

Molecular Oncology and the EACR: new partners in communicating and supporting cancer research.

01-06-2023

Molecular oncology

Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.

01-06-2023

Clinical and translational medicine

Drug-drug synthetic lethality to combat cancer: From bench to bedside.

01-05-2023

Angiogenesis

Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy.

01-05-2023

Nature reviews. Gastroenterology & hepatology

Evolving therapeutic landscape of advanced hepatocellular carcinoma.

01-04-2023

Molecular oncology

More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics.

01-03-2023

Nature reviews. Drug discovery

Rational combinations of targeted cancer therapies: background, advances and challenges.

01-03-2023

Nature cancer

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF^V600E colorectal tumors.

01-02-2023

EBioMedicine

Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer.

01-01-2023

Cell research

RASON, a new player in cancer's Premier League.

01-01-2023

Molecular cancer therapeutics

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.

02-12-2022

Cell reports. Medicine

Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer.

15-11-2022

Nature cancer

cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis.

01-11-2022

PloS one

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.

07-09-2022

Life science alliance

Genetic and compound screens uncover factors modulating cancer cell response to indisulam.

01-09-2022

Cell discovery

EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma.

23-08-2022

iScience

Identifying mutant-specific multi-drug combinations using comparative network reconstruction.

19-08-2022

Nature communications

DNA damage-induced transcription stress triggers the genome-wide degradation of promoter-bound Pol II.

24-06-2022

NPJ breast cancer

Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant.

08-06-2022

Nature reviews. Cancer

Exploiting senescence for the treatment of cancer.

01-06-2022

Cell genomics

A large-scale organoid-based screening platform to advance drug repurposing in pancreatic cancer.

09-02-2022

Genome medicine

Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.

18-10-2021

Nature reviews. Gastroenterology & hepatology

Exploring liver cancer biology through functional genetic screens.

01-10-2021

Molecular cancer research : MCR

Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen.

01-10-2021

Molecular oncology

Playing cancer at its own game: activating mitogenic signaling as a paradoxical intervention.

01-08-2021

Nature reviews. Clinical oncology

Precision oncology in metastatic colorectal cancer - from biology to medicine.

01-08-2021

Cell reports

The Cancer SENESCopedia: A delineation of cancer cell senescence.

27-07-2021

Nature cell biology

Publisher Correction: Elongation factor ELOF1 drives transcription-coupled repair and prevents genome instability.

01-07-2021

Nature

EGFR activation limits the response of liver cancer to lenvatinib.

01-07-2021

Nature cell biology

Elongation factor ELOF1 drives transcription-coupled repair and prevents genome instability.

01-06-2021

Cancer discovery

Thinking Differently about Cancer Treatment Regimens.

01-05-2021

The oncologist

Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.

01-04-2021

Cancers

Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells.

05-03-2021

Genome medicine

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

10-02-2021

British journal of cancer

Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib.

01-01-2021